SCHEMBL9052336

SCHEMBL9052336

O=C(CCCN1CCC(O)(c2ccc(F)cc2)CC1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 14/20 0.91
▸ CYP1A2 P05177 2/20 0.79
▸ CYP3A4 P08684 2/20 0.79
▸ HTR1A P08908 2/20 0.79
▸ ADRA2A P08913 2/20 0.79
▸ CYP2D6 P10635 2/20 0.79
▸ CHRM1 P11229 2/20 0.79
▸ ADRA2B P18089 2/20 0.79
▸ ADRA2C P18825 2/20 0.79
▸ CHRM3 P20309 2/20 0.79
▸ SLC6A2 P23975 2/20 0.79
▸ HTR2A P28223 2/20 0.79
▸ SLC6A4 P31645 2/20 0.79
▸ ADRA1A P35348 2/20 0.79
▸ HRH1 P35367 2/20 0.79
▸ OPRM1 P35372 2/20 0.79
▸ DRD3 P35462 2/20 0.79
▸ HTR2B P41595 2/20 0.79
▸ SLC6A3 Q01959 2/20 0.79
▸ KCNH2 Q12809 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8986042 0.95 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
SCHEMBL9054984 0.94 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
SCHEMBL8986029 0.91 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
Haloperidol SCHEMBL4113148 0.89 DRD2 (0.83) DRD2CYP1A2CYP3A4HTR1AADRA2A
SCHEMBL20254453 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
Moperone SCHEMBL34340 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
Haloperidol SCHEMBL5070670 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
Haloperidol SCHEMBL8264 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
SCHEMBL20653047 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A
Bromperidol SCHEMBL43755 0.88 DRD2 (1.00) DRD2CYP1A2CYP3A4HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10253035-B2 Eis inhibitors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2019-04-09 — — US disclosed
US-20190015400-A1 Antifungal Compositions UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2019-01-17 — — US disclosed
US-20180162867-A1 EIS INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2018-06-14 — — US disclosed
WO-1996002250-A1 HALOPERIDOL ANALOGS AND THE USE THEREOF ACEA PHARMACEUTICALS INC. (US) 1996-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190015400-A1 Antifungal Compositions DPM1, HNMT, ERG28 DRD2 301/4885CYP1A2 133/4885CYP3A4 448/4885
US-20180162867-A1 EIS INHIBITORS EP300, ACAT1, ACAT2 DRD2 4655/4885CYP1A2 2742/4885CYP3A4 2595/4885
US-10253035-B2 Eis inhibitors EP300, ACAT1, ACAT2 DRD2 4655/4885CYP1A2 2742/4885CYP3A4 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback